<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439738</url>
  </required_header>
  <id_info>
    <org_study_id>CVAH631BUS06</org_study_id>
    <nct_id>NCT00439738</nct_id>
  </id_info>
  <brief_title>Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults</brief_title>
  <official_title>A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the blood pressure lowering efficacy of
      valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of
      obese hypertensive (mean sitting systolic blood pressure [MSSBP] &gt;150 mmHg) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Sitting Systolic Blood Pressure (MSSBP)</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Sitting Diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>Baseline to Weeks 4, 8, 12 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Blood Pressure (BP) Control by Visit (&lt; 140/90 mm Hg)</measure>
    <time_frame>Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)</time_frame>
    <description>Mean sitting systolic blood pressure/mean sitting diastolic blood pressure &lt; 140/90 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Blood Pressure (BP)Control by Visit (&lt; 130/80 mm Hg)</measure>
    <time_frame>Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)</time_frame>
    <description>Mean sitting systolic blood pressure/mean sitting diastolic blood pressure &lt; 130/80 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Glucose</measure>
    <time_frame>Week 16</time_frame>
    <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Insulin</measure>
    <time_frame>Week 16</time_frame>
    <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Non-esterified Fatty Acids</measure>
    <time_frame>Week 16</time_frame>
    <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">412</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>valsartan/HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ +Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCTZ + Amlodipine</intervention_name>
    <description>12.5 mg HCTZ capsules
25 mg HCTZ capsules
5 mg amlodipine capsules
10 mg amlodipine capsules</description>
    <arm_group_label>HCTZ +Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan/HCTZ</intervention_name>
    <description>160 mg film-coated valsartan tablets
320 mg film-coated valsartan tablets
12.5 mg HCTZ capsules
25 mg HCTZ capsules</description>
    <arm_group_label>valsartan/HCTZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40 years of age or older

          -  Moderate or severe high blood pressure defined as systolic blood pressure (the top
             number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom
             number) less then 110 mmHg

          -  Central (abdominal) obesity

        Exclusion Criteria:

          -  Systolic blood pressure (the top number) greater than or equal to 180 mmHg and
             diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg

          -  Currently taking more then 3 medications to treat high blood pressure

          -  Inability to stop all current blood pressure medications if any up to 4 weeks

          -  History of Type 1 or Type 2 diabetes

          -  History of stroke, mini-stroke (transient ischemic attack) or heart attack within the
             last 6 months

          -  History of or current diagnosis of congestive heart failure

          -  History of cancer within the past 5 years with the exception of localized basal cell
             carcinoma or squamous cell carcinoma

          -  Women who are pregnant or nursing

          -  Alcohol or drug abuse within the last 2 years

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Terence T. Hart, MD</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Research</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cardiovascular &amp; Hypertension</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Tarrant Internal Medicine Assoc</name>
      <address>
        <city>Euless</city>
        <state>Texas</state>
        <zip>76040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frandsen Family Medicine</name>
      <address>
        <city>Port Orchard</city>
        <state>Washington</state>
        <zip>98366</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2574</url>
    <description>Results for CVAH631BUS06 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2007</study_first_posted>
  <results_first_submitted>November 5, 2008</results_first_submitted>
  <results_first_submitted_qc>February 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2009</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Obesity, hypertension, valsartan/hydrochlorothiazide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
        </group>
        <group group_id="P2">
          <title>HCTZ +Amlodipine</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Lab Values</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
        </group>
        <group group_id="B2">
          <title>HCTZ +Amlodipine</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="206"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="412"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172" spread="83.5"/>
                    <measurement group_id="B2" value="180" spread="87.4"/>
                    <measurement group_id="B3" value="352" spread="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="16.5"/>
                    <measurement group_id="B2" value="26" spread="12.6"/>
                    <measurement group_id="B3" value="60" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Sitting Systolic Blood Pressure (MSSBP)</title>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Intent to Treat (ITT), Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
          </group>
          <group group_id="O2">
            <title>HCTZ +Amlodipine</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Systolic Blood Pressure (MSSBP)</title>
          <population>Intent to Treat (ITT), Last Observation Carried Forward (LOCF)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.7" spread="7.81"/>
                    <measurement group_id="O2" value="159.0" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.2" spread="16.26"/>
                    <measurement group_id="O2" value="137.5" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="15.61"/>
                    <measurement group_id="O2" value="-21.5" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Sitting Diastolic Blood Pressure (MSDBP)</title>
        <time_frame>Baseline to Weeks 4, 8, 12 and 16</time_frame>
        <population>Intent to Treat (ITT), Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
          </group>
          <group group_id="O2">
            <title>HCTZ +Amlodipine</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Diastolic Blood Pressure (MSDBP)</title>
          <population>Intent to Treat (ITT), Last Observation Carried Forward (LOCF)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" spread="7.94"/>
                    <measurement group_id="O2" value="93.6" spread="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" spread="9.38"/>
                    <measurement group_id="O2" value="87.6" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" spread="9.87"/>
                    <measurement group_id="O2" value="85.1" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" spread="9.14"/>
                    <measurement group_id="O2" value="82.8" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" spread="10.14"/>
                    <measurement group_id="O2" value="80.9" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="9.90"/>
                    <measurement group_id="O2" value="-12.7" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Blood Pressure (BP) Control by Visit (&lt; 140/90 mm Hg)</title>
        <description>Mean sitting systolic blood pressure/mean sitting diastolic blood pressure &lt; 140/90 mm Hg</description>
        <time_frame>Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
          </group>
          <group group_id="O2">
            <title>HCTZ +Amlodipine</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Blood Pressure (BP) Control by Visit (&lt; 140/90 mm Hg)</title>
          <description>Mean sitting systolic blood pressure/mean sitting diastolic blood pressure &lt; 140/90 mm Hg</description>
          <population>Intent to Treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Blood Pressure (BP)Control by Visit (&lt; 130/80 mm Hg)</title>
        <description>Mean sitting systolic blood pressure/mean sitting diastolic blood pressure &lt; 130/80 mm Hg</description>
        <time_frame>Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
          </group>
          <group group_id="O2">
            <title>HCTZ +Amlodipine</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Blood Pressure (BP)Control by Visit (&lt; 130/80 mm Hg)</title>
          <description>Mean sitting systolic blood pressure/mean sitting diastolic blood pressure &lt; 130/80 mm Hg</description>
          <population>Intent to Treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Glucose</title>
        <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
        <time_frame>Week 16</time_frame>
        <population>Only those patients who completed the study through week 16 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
          </group>
          <group group_id="O2">
            <title>HCTZ +Amlodipine</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Glucose</title>
          <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
          <population>Only those patients who completed the study through week 16 were included in this analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline visit (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" spread="15.91"/>
                    <measurement group_id="O2" value="99.4" spread="19.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" spread="15.68"/>
                    <measurement group_id="O2" value="102.8" spread="17.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 16 (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="13.71"/>
                    <measurement group_id="O2" value="3.4" spread="18.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline visit (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.9" spread="47.18"/>
                    <measurement group_id="O2" value="127.7" spread="40.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.3" spread="49.52"/>
                    <measurement group_id="O2" value="146.5" spread="56.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 16 (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="38.21"/>
                    <measurement group_id="O2" value="18.9" spread="40.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Insulin</title>
        <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
        <time_frame>Week 16</time_frame>
        <population>Only those patients who completed the study through week 16 were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
          </group>
          <group group_id="O2">
            <title>HCTZ +Amlodipine</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Insulin</title>
          <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
          <population>Only those patients who completed the study through week 16 were included in this analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline visit (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.66" spread="20.435"/>
                    <measurement group_id="O2" value="20.37" spread="20.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.45" spread="26.039"/>
                    <measurement group_id="O2" value="23.62" spread="19.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 16 (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="28.427"/>
                    <measurement group_id="O2" value="3.67" spread="19.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline visit (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.04" spread="82.183"/>
                    <measurement group_id="O2" value="95.95" spread="76.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.04" spread="129.880"/>
                    <measurement group_id="O2" value="120.01" spread="100.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 16 (120 minute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.68" spread="90.094"/>
                    <measurement group_id="O2" value="28.07" spread="71.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Non-esterified Fatty Acids</title>
        <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
        <time_frame>Week 16</time_frame>
        <population>Only those patients who completed the study through week 16 were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan/HCTZ (Hydrochlorothiazide)</title>
          </group>
          <group group_id="O2">
            <title>HCTZ +Amlodipine</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Non-esterified Fatty Acids</title>
          <description>After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test</description>
          <population>Only those patients who completed the study through week 16 were included in this analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline visit (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.208"/>
                    <measurement group_id="O2" value="0.47" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.194"/>
                    <measurement group_id="O2" value="0.47" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 16 (0 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.249"/>
                    <measurement group_id="O2" value="0.00" spread="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline visit (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.090"/>
                    <measurement group_id="O2" value="0.10" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.093"/>
                    <measurement group_id="O2" value="0.10" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 16 (120 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.117"/>
                    <measurement group_id="O2" value="-0.01" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>1-862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

